The cell of origin and the leukemia stem cell in acute myeloid leukemia
The cell of origin and the leukemia stem cell in acute myeloid leukemia
复制标题
DOI：
10.1002/gcc.22805
复制
发表时间：
2019-08-31
影响因子：
3.7
通讯作者：
Bohlander, Stefan K.
中科院分区：
文献类型：
--
作者：
Chopra, Martin;Bohlander, Stefan K.
有实验和观察证据表明，急性髓性白血病（AML）的白血病克隆细胞具有不同的表型，即使它们具有相同的体细胞突变。AML恶性克隆的组织与正常造血有许多相似之处，白血病干细胞（LSCs）维持白血病并产生更多分化的细胞。LSCs，类似于正常的造血干细胞（hsc），当移植到受体体内时，能够产生新的白血病克隆细胞。白血病起源细胞（COL）被定义为能够转化为白血病细胞的正常细胞。目前的证据表明，COL与LSC不同。在这里，我们将回顾当前关于AML中LSCs和COL的知识。
There is experimental and observational evidence that the cells of the leukemic clone in acute myeloid leukemia (AML) have different phenotypes even though they share the same somatic mutations. The organization of the malignant clone in AML has many similarities to normal hematopoiesis, with leukemia stem cells (LSCs) that sustain leukemia and give rise to more differentiated cells. LSCs, similar to normal hematopoietic stem cells (HSCs), are those cells that are able to give rise to a new leukemic clone when transplanted into a recipient. The cell of origin of leukemia (COL) is defined as the normal cell that is able to transform into a leukemia cell. Current evidence suggests that the COL is distinct from the LSC. Here, we will review the current knowledge about LSCs and the COL in AML.